Cytokines, spatial activation and tumor infiltration: the future of immunotherapy
Cancer immunotherapy is a constantly advancing research area, playing a vital role in combating cancer. A central aspect of this field is the study of cytokines, essential signaling molecules that coordinate immune responses against malignancies. However, utilizing cytokines specifically and effectively in cancer therapy is complex and multifaceted. This is where spatial biology comes into play, offering insights into cytokines signaling within the tumor microenvironment (TME). This advanced perspective enhances our comprehension of cytokine-mediated immune responses and refines the strategies for their therapeutic application. This blog thoroughly examines cytokine’s crucial role in cancer immunotherapy. It investigates how advancements in spatial biology support the development of more effective and targeted therapeutics by revealing the intricate interactions and spatial dynamics of cells within tumors.
The role of cytokines in immunotherapy
With the development of immunotherapy, there is a rising emphasis on using innate host defense mechanisms to combat cancer. Among them, cytokines, small signalling proteins secreted by cells, play an essential role in mediating cell communication, localization and interaction. They are produced by various cell types, with helper T cells (Th) and macrophages being the primary sources1. Cytokines actively engage immune effector and stromal cells in the tumor environment, thereby improving the ability of cytotoxic effector cells to recognize and target the tumor. This unique property has led to intensified research efforts to characterize cytokines and utilize their extensive signaling networks for the design of novel cancer therapies2.
Despite the FDA‘s approvals of Interleukin-2 (IL-2) and Interferon-alpha (IFN–ɑ) for cancer treatment, the clinical success of cytokines has been limited3,4. This is primarily due to their restricted therapeutic applications and the occurrence of dose-limiting toxicities5. For example, high doses of IFN–α can lead to severe flu-like side effects characterized by fatigue, fever, headaches, muscle pain, or gastrointestinal issues6. Therefore, a significant contrast exists between the body’s natural, precise use of cytokines and the broader, less targeted approach typically seen in external cytokine therapies. Internally, cytokines are deployed in specific and tightly controlled time, dose, and place, addressing targeted areas as needed. Conversely, external therapies often involve a systemic distribution, which lacks the refined specificity of the body’s innate mechanisms. In addition, cytokines can influence various cell types, and this broad impact can create complexities in developing targeted and, thus, effective therapies.
Recent advancements in protein engineering have emerged as pivotal solutions to these challenges. By fine-tuning the aspects of cytokine therapy — specifically the timing, location, specificity, and duration of cytokine activity — protein engineering is bridging the gap. It enables systemically administered cytokines to resemble more the body’s natural cytokine biology. This approach can potentially enhance the efficacy and safety of cytokine-based treatments, offering a more sophisticated and targeted strategy that aligns with the body’s biological processes, while limiting off-target and side effects.
Advancing cytokine-based therapies through spatial insights
Cancer immunotherapy relies heavily on understanding the tumor microenvironment, where cancer, immune, stroma cells, and other biological and chemical components interact. Multiplex immunofluorescence (mIF) provides a window into these interactions by:
- Characterizing cell populations: it can reveal the presence, abundance, and organization of both immune and stromal cells within the tumor, which is critical for understanding tumor biology and the immune response.
- Analyzing cell activation: it allows scientists to assess the activity state of each of the cell populations through biomarker expression and spatial organization and extract insights on the tumor immunogenicity.
- Highlighting tumor heterogeneity and clinical response: by combining the presence, organization, and activity state of cells composing the TME, it helps understand the tumor heterogeneity and correlate it with the patient’s clinical benefit from cancer therapies.
- Revealing spatial biomarkers associated with therapy response: using mIF to analyze tumor biopsies before and after therapeutic intervention can help identify or validate candidate predictive biomarkers.
Recent technological advancements, such as the Lunaphore COMET™ system, have pushed the boundaries of what is possible with mIF. This system performs runs of 40 markers in a fully–automated manner using label-free antibodies, allowing for deep characterization of the TME. A recent study presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, Werewolf Therapeutics leveraged the COMET™ platform to analyze the effects on TME of various engineered and systemically administered cytokines using a mice model. The authors presented four studies on inducible cytokines (INDUKINE™), where they used mIF as an effective validation assay that further uncovers spatial parameters of immune activation following therapeutic intervention (Figure 1 and Figure 2).
Embracing multiomics approaches: capturing the complete picture of cytokine signaling in the tumor microenvironment
In the exploration of the TME, and especially for the role of secreted molecules like cytokines, it is essential to recognize the importance of multiomics approaches. Indeed, due to the secretion of cytokines by cells in the TME, staining of both RNA and protein can ensure the complete capture of all signaling players and molecules within their spatial context. Thus, by integrating RNA and protein data, we gain a more comprehensive understanding of the signaling activities. On COMET™, it is possible to perform fully-automated detection of RNA and protein using RNAscope™ and sequential immunofluorescence8 on FFPE samples with subcellular resolution (Figure 3). Read more here.
The journey through the complex world of cytokines in cancer immunotherapy, illuminated by the advancements in spatial biology, demonstrates the remarkable potential as well as the current challenges in this field. As we have explored, cytokines play a fundamental role in mediating immune responses within the TME. However, their effective therapeutic application is fraught with challenges, from dose-limiting toxicities to their broad targeting of various cell types. The arise of techniques like multiplex immunofluorescence, particularly with cutting-edge platforms like Lunaphore’s COMET™, has significantly enhanced our ability to visualize and understand these dynamics with unprecedented amount of precision, information, and details. Moreover, the integration of RNA and protein data in multiomics approaches promises a more accurate and holistic understanding of cytokine signalling and interactions, paving the way for more precise and effective cancer treatments. As research continues to push the boundaries of our understanding, the future of cytokine-based therapies in oncology appears increasingly promising; offering hope for more personalized, effective, and safer treatment options for cancer patients.
Download the SITC 2023 posters to catch-up with the latest advances in cytokine research
Access the full studies and learn more on the promises of inducible cytokine therapy by clicking the links below.
Download the posters
- Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment
- The Combination of ACT and INDUKINE™ Therapy Leads to Improved Antitumor Immunity in Mouse Solid Tumors
- Development of WTX-712, a Conditionally Active IL-21 INDUKINETM Molecule for the Treatment of Cancer
- Spatial Analysis of Tumor Infiltrating Lymphocyte Populations in Syngeneic Mouse Tumor Models After Treatment with IL-12 (mWTX-330) or IL-2 (WTX-124) INDUKINE™ Molecules
- Integration of RNA in situ hybridization and sequential immunofluorescence for same-slide fully automated multiomics analysis of the tumor microenvironment
- Zhang J and An J. Cytokines, Inflammation and Pain. Int Anesthesiol Clin. 2007. 45(2):27-37. doi: 10.1097/AIA.0b013e318034194e.
- Lee S and Margolin K. Cytokines in Cancer Immunotherapy. Cancers. 2011. 3(4):3856-93. doi: 10.3390/cancers3043856.
- Rosenberg S. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014. 192(12):5451-8. doi:10.4049/jimmunol.1490019.
- Product information Proleukin (aldesleukin). www.fda.gov, accessed December 08, 2023.
- Santollani L and Wittruo K. Spatiotemporally programming cytokine immunotherapies through protein engineering. Immunol Rev. 2023. 320(1):10-28. doi: 10.1111/imr.13234.
- Waldmann T. Cytokines in Cancer Immunotherapy. Cold Spring Harb Perspect Biol. 2018. 10(12):a028472. doi: 10.1101/cshperspect.a028472.
- Nirschl C. et al. mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8 T and NK Cells to Generate Antitumor Immunity. Cancer Immunol Res. 11(7):962-977. doi: 10.1158/2326-6066.CIR-22-0705.
- Rivest F et al. Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics. Sci Rep. 2023. 13(1):16994. doi: 10.1038/s41598-023-43435-w.